A phase II trial combining the anti-LAG-3 agent, immutep, and pembrolizumab (NCT03625323) for first-line metastatic NSCLC patients unselected for PD-L1, also showed encouraging results [71]. Here, CD274 is linked to non-small cell lung carcinoma.